The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

K Dheda, T Gumbo, G Maartens, KE Dooley… - The lancet Respiratory …, 2017 - thelancet.com
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Tuberculous meningitis: progress and remaining questions

J Huynh, J Donovan, NH Phu, HDT Nghia… - The Lancet …, 2022 - thelancet.com
Tuberculous meningitis is a devastating brain infection that is caused by Mycobacterium
tuberculosis and is notoriously difficult to diagnose and treat. New technologies …

[图书][B] WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update

World Health Organization - 2022 - books.google.com
The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies

F Mota, CA Ruiz-Bedoya, EW Tucker, DP Holt… - Nature …, 2022 - nature.com
Pretomanid is a nitroimidazole antimicrobial active against drug-resistant Mycobacterium
tuberculosis and approved in combination with bedaquiline and linezolid (BPaL) to treat …

Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs

MGG Sturkenboom, AG Märtson, EM Svensson… - Clinical …, 2021 - Springer
Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline

MC Cholo, MT Mothiba, B Fourie… - Journal of Antimicrobial …, 2016 - academic.oup.com
Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

Treatment of tuberculous meningitis and its complications in adults

A Davis, G Meintjes, RJ Wilkinson - Current treatment options in neurology, 2018 - Springer
Purpose of review Tuberculous meningitis (TBM) is a global health problem. In this review,
we systematically evaluate the evidence for current and emerging antimicrobials, host …

New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians

JM Aguilar Diaz, AA Abulfathi, LH Te Brake… - Respiration, 2023 - karger.com
Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Long term outcomes of patients with tuberculous meningitis: the impact of drug resistance

EE Evans, T Avaliani, M Gujabidze, T Bakuradze… - PLoS …, 2022 - journals.plos.org
Background Little is known about the impact of drug-resistance on clinical outcomes among
patients with tuberculosis meningitis (TBM). Methods A retrospective cohort study among …

[HTML][HTML] Pretomanid resistance: an update on emergence, mechanisms and relevance for clinical practice

TVA Nguyen, QH Nguyen, TNT Nguyen… - International Journal of …, 2023 - Elsevier
Abstract Pretomanid (PA-824), a novel anti-tuberculosis nitroimidazoxazine, has been
approved for multidrug-resistant tuberculosis treatment for a few years. Pretomanid has …